Fatal Breakthrough Mucormycosis in an Acute Myelogenous Leukemia Patient while on Posaconazole Prophylaxis

Seung Hun Kang(Catholic University of Korea), Hee‐Je Kim(St. Mary's Hospital), Dong‐Gun Lee(Korea University), Jihye Kim(Seoul National University), Kwan Yong Lee(Catholic University of Korea), Ji Yeon Yoo(Catholic University of Korea), Myoung Nam Bae(Catholic University of Korea), Hyun Seon Kim(Catholic University of Korea)
Infection and Chemotherapy
January 1, 2015
10.3947/ic.2015.47.1.49
Cited by 18

Related Papers

Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium
|The Lancet Infectious Diseases|2019|1.7k
Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2023|390
Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of <i>FLT3</i>
|Journal of Clinical Oncology|2024|204
Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial
|The Lancet|2021|202
Myosin regulatory light chains are required to maintain the stability of myosin II and cellular integrity
|Biochemical Journal|2011|132